These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17278713)

  • 1. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.
    Durmanová V; Sapák M; Kosovský J; Rezuchová I; Kúdelová M; Buc M; Rajcáni J
    Folia Microbiol (Praha); 2008; 53(1):73-83. PubMed ID: 18481222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
    Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
    Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
    Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
    J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
    Frye TD; Chiou HC; Hull BE; Bigley NJ
    Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
    Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
    Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
    Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
    Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].
    Arefian E; Bamdad T; Soleimanjahi H; Akhood MR; Parsania M; Ghaemi A
    Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction of herpes simplex virus type I glycoprotein D DNA vaccine and its preliminary study].
    Zhu MZ; Liu HW; Liu XJ; Han YH; Yang BL; Song GX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):67-70. PubMed ID: 12905843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
    J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
    Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
    Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of apoptotic and anti-apoptotic genes on efficacy of DNA vaccine encoding glycoprotein B of Herpes Simplex Virus type 1.
    Parsania M; Bamdad T; Hassan ZM; Kheirandish M; Pouriayevali MH; Sari RD; Jamali A
    Immunol Lett; 2010 Feb; 128(2):137-42. PubMed ID: 20026118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
    Ghaemi A; Soleimanjahi H; Bamdad T; Soudi S; Arefeian E; Hashemi SM; Ebtekar M
    Comp Immunol Microbiol Infect Dis; 2007 Jul; 30(4):197-210. PubMed ID: 17335902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1.
    Lowry PW; Koropchak CM; Choi CY; Mocarski ES; Kern ER; Kinchington PR; Arvin AM
    Antiviral Res; 1997 Feb; 33(3):187-200. PubMed ID: 9037375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eucaryotic expression and bioactivity analysis of the recombinant HSV-gD1].
    Wang Z; Li L; Guan W; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2010 May; 26(5):657-63. PubMed ID: 20684311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-inducing properties of a prototype bivalent herpes simplex virus/enterotoxigenic Escherichia coli DNA vaccine.
    Lásaro MO; Alves AM; Botosso VF; Durigon EL; Ferreira LC
    FEMS Immunol Med Microbiol; 2003 Jan; 35(1):25-31. PubMed ID: 12589954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.